Telomerase as a possible target for anticancer therapy

Chemistry and Biology

Volumn 6, Issue 11, 1999, Pages

  Autexier, Chantal ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; EUKARYOTA;

EID: 0033229856     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80122-7     Document Type: Short Survey

References (61)

1. Morin, G.B. (1989). The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59, 521-529.
2. Greider, C.W. (1996). Telomere length regulation. Annu. Rev. Biochem. 65, 337-365.
3. Colgin, L.M. & Reddel, R.R. (1999). Telomere maintenance mechanisms and cellular immortalisation. Curr. Opin. Genet. Dev. 9, 97-103.
4. Pardue, M-L. & DeBaryshe, P.G. (1999). Telomeres and telomerase: More than the end of the line. Chromosoma 108, 73-82.
5. Nugent, C.I. & Lundblad, V. (1998). The telomerase reverse transcriptase: Components and regulation. Genes Dev. 12, 1073-1085.
6. Vaziri, H. & Benchimol, S. (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279-282.
7. Counter, C.M., et al., & Weinberg, R.A. (1998). Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16, 1217-1222.
8. Weinrich, S.L., et al., & Morin, G.B. (1997). Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 17, 498-502.
9. Beattie, T.L., Zhou, W., Robinson, M.O. & Harrington, L. (1998). Reconstitution of human telomerase activity in vitro. Curr. Biol. 8, 177-180.
10. Autexier, C. & Greider, C.W. (1996). Telomerase and cancer: Revisiting the telomere hypothesis. Trends Biochem. Sci. 21, 387-391.
11. De Lange, T., et al., & Varmus, H.E. (1990). Structure and variability of human chromosome ends. Mol. Cell. Biol. 10, 518-527.
12. Shay, J.W. & Bacchetti, S. (1997). A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791.
13. Pitts, A.E. & Corey, D.R. (1999). The telomerase challenge - An unusual problem in drug discovery. Drug Discov. Today 4, 155-161.
14. Blasco, M.A. et al., & Greider, C.W. (1997). Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34.
15. Lee, H.-W., Blasco, M.A., Gottlieb, G.J., Horner, J.W., Greider, C.W. & DePinho, R.A. (1998). Essential role of mouse telomerase in highly proliferative organs. Nature 392, 569-574.
16. Mata, J.E., et al., & Iversen, P.L. (1997). A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Tox. App. Pharmacol. 144, 189-197.
17. Kondo, S., Kondo, Y., Li, G., Silverman, R.H. & Cowell, J.K. (1998). Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16, 3323-3330.
18. Kondo Y., Kondo S., Tanaka, Y., Haqqi, T., Barna, B.P. & Cowell, J.K. (1998). Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16, 2243-2248.
19. Singer, M.S. & Gottschling, D.E. (1994). TLC1 : Template RNA component of Saccharomyces cerevisiae telomerase. Science 266, 404-409.
20. McEachern, M.J. & Blackburn, E.H. (1995). Runaway telomere elongation caused by telomerase RNA gene mutations. Nature 376, 403-409.
21. Nakamura, T.M., Cooper, J.P. & Cech, T.R. (1998). Two modes of survival of fission yeast without telomerase. Science 282, 493-496.
22. Bryan, T.M. & Reddel, R.R. (1997). Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur. J. Cancer 33, 767-773.
23. Yu, G-L., Bradley, J.D., Attardi, L.D. & Blackburn, E.H. (1990). In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 344, 126-132.
24. Feng, J., et al., & Villeponteau, B. (1995). The human telomerase RNA component. Science 269, 1236-1241.
25. Strahl, C. & Blackburn, E.H. (1996). Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16, 53-65.
26. Sun, D., et al., & Hurley, L.H. (1997). Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40, 2113-2116.
27. Kanazawa, Y., et al., & Hayashi, N. (1996). Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225, 570-576.
28. Norton, J.C., Piatyszek, M.A., Wright, W.E., Shay, J.W. & Corey, D.R. (1996). Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14, 615-619.
29. Gomez, D.E., Tejera, A.M. & Olivero, O.A. (1998). Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246, 107-110.
30. Fletcher, T.M., Salazar, M. & Chen, S-F. (1996). Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry 35, 15611-15617.
31. Pai, R.B., Pai, S.B., Kukhanova, M., Dutschman, G.E., Guo, X. & Cheng, Y-C. (1998). Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues. Cancer Res. 58, 1909-1913.
32. Yegorov, Y.E., Chernov, D.N., Akimov, S.S., Bolsheva, N.L., Krayevsky, A.A. & Zelenin, A.V. (1996). Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett. 389, 115-118.
33. 4 in vitro. Biochem. Biophys. Res. Commun. 251, 620-624.
34. Yokoyama, Y., et al., & Tamaya, T. (1998). Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58, 5406-5410.
35. Wan, M.S.K., Fell, P.L. & Akhtar, S. (1998). Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8, 309-317.
36. Wellinger, R.J. & Sen, D. (1997). The DNA structures at the ends of eukaryotic chromosomes. Eur. J. Cancer 33, 735-749.
37. Izbicka, E., et al. & Von Hoff, D.D. (1999). Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 59, 639-644.
38. Fedoroff, O.Y., Salazar, M., Han, H., Chemeris, V.V., Kerwin, S.M. & Hurley, L.H. (1998). NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry 37, 12367-12374.
39. Nakamura, T.M., et al., & Cech, T.R. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959.
40. Avilion, A.A., Piatyszek, M., Gupta, J., Shay, J., Bacchetti, S. & Greider, C.W. (1996). Human telomerase RNA and telomerase activity levels in immortal cell lines and tumor tissues. Cancer Res. 56, 645-650.
41. Kolquist, K.A., et al., & Gerald, W.L. (1998). Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat. Genet. 19, 182-186.
42. Hahn, W.C. et al., & Weinberg, R.A. (1999). Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5, 1164-1170.
43. Zhang, X., Mar, V, Zhou, W., Harrington, L. & Robinson, M.O. (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13, 2388-2399.
44. Corey, D.R. (1997). Peptide nucleic acids: Expanding the scope of nucleic acid recognition. Trends Biotechnol. 15, 224-229.
45. Hamilton, S.E., Simmons, C.G., Kathiriya, I.S. & Corey, D.R. (1999). Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6, 343-351.
46. Hamilton, S.E., et al., & Corey, D.R. (1997). Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry 36, 11873-11880.
47. Pitts, A.E. & Corey, D.R. (1998). Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl Acad. Sci. USA 95, 11549-11554.
48. Kirk, K.E., Harmon, B.P., Reichardt, I.K., Sedat, J.W. & Blackburn, E.H. (1997). Block in anaphase chromosome separation caused by a telomerase template mutation. Science 275, 1478-1481.
49. Bodnar, A.G., et al., & Wright, W.E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
50. Kondo, S., et al., & Barna, B.P. (1998). Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12, 801-811.
51. Muller, A., Saretzki, G. & von Zglinicki, T. (1998). Telomerase inhibition by induced expression of antisense RNA. Adv. Exp. Med. Biol. 451, 23-26.
52. Bisoffi, M., et al., & Griffith, J.K. (1998). Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA. Eur. J. Cancer 34, 1242-1249.
53. Sharma, H.W., Hsiao, R. & Narayanan, R. (1996). Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev. 6, 3-7.
54. Matthes, E. & Lehmann, C. (1999). Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res. 27, 1152-1158.
55. Ohnuma, T., Li, F-L. & Holland, J.F. (1997). Inhibitory effects of telomere-mimic phosphorothioate oligonucleotides on various human tumor cells in vitro. Anticancer Res. 17, 2455-2458.
56. Duncan, V.E., Ajmani, P.S. & Hughes, J.A. (1998). Cellular delivery is a major obstacle for oligodeoxynucleotide inhibition of telomerase activity. Anticancer Res. 18, 4105-4108.
57. Glukhov, A.I., Zimnik, O.V., Gordeev, S.A. & Severin, S.E. (1998). Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem. Biophys. Res. Commun. 248, 368-371.
58. Harrison, J.G., Frier, C., Laurent, R., Dennis, R., Raney, K.D. & Balasubramanian, S. (1999). Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorg. Med. Chem. Lett. 9, 1273-1278.
59. Perry, P.J., et al., & Neidle, S. (1998). 1,4- and 2,6-disubstituted amidoanthracene-9, 10-dione derivatives as inhibitors of human telomerase. J. Med. Chem. 41, 3253-3260.
60. Wheelhouse, R.T., Sun, D., Han, H., Han, F.X. & Hurley, L.H. (1998). Cationic porphyrins as telomerase inhibitors: The interaction of tetra-(N-methyl-4-pyridyl) porphine with quadruplex DNA. J. Am. Chem. Soc. 120, 3261-3262.
61. Burger, A.M., Double, J.A. & Newell, D.R. (1997). Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer 33, 638-644.